Tenidap in patients with rheumatoid arthritis. A 4-week, placebo-controlled study. 1996

H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
University of Nevada, Reno School of Medicine 89503, USA.

The present double-blind, placebo-controlled study was conducted to compare the safety and efficacy of tenidap in patients with rheumatoid arthritis (RA). Patients with flare of active RA following NSAID withdrawal were randomized to receive either placebo (n = 67) or tenidap (n = 131; 40-200 mg/day). The mean changes from baseline in efficacy and biochemical variables were compared between treatment groups at endpoint (4 weeks). The improvements in four of the five primary efficacy variables were significantly greater in the tenidap group compared with the placebo group (p < 0.01). Tenidap was also associated with an 18% reduction in erythrocyte sedimentation rate (ESR) and a marked, 51%, reduction in serum C-reactive protein (CRP) level, both of which were significantly greater than the changes in the placebo group (p < 0.05). The percentage of patients who discontinued because of side effects was the same in both groups (3%). In conclusion, tenidap 40-200 mg/day was effective and well tolerated in the treatment of patients with RA for 4 weeks.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004064 Digestive System A group of organs stretching from the MOUTH to the ANUS, serving to breakdown foods, assimilate nutrients, and eliminate waste. In humans, the digestive system includes the GASTROINTESTINAL TRACT and the accessory glands (LIVER; BILIARY TRACT; PANCREAS). Ailmentary System,Alimentary System
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078183 Oxindoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl and a carbonyl at the pyrrole ring typically at the 2-position. Ajmalicine Oxindole,Ajmalicine Oxindoles,Ajmalicine-Type Oxindole,Ajmalicine-Type Oxindoles,Indolinone,Indolinone Derivative,Macroline Oxindole,Macroline Oxindoles,Macroline-Type Oxindole,Macroline-Type Oxindoles,Oxazolidinone Derivative,Oxindole Alkaloid,Oxindole Alkaloid Derivative,Oxindole Derivative,Indolinone Derivatives,Indolinones,Oxazolidinone Derivatives,Oxindole Alkaloid Derivatives,Oxindole Alkaloids,Oxindole Derivatives,Ajmalicine Type Oxindole,Ajmalicine Type Oxindoles,Alkaloid Derivative, Oxindole,Alkaloid, Oxindole,Derivative, Indolinone,Derivative, Oxazolidinone,Derivative, Oxindole,Derivative, Oxindole Alkaloid,Macroline Type Oxindole,Macroline Type Oxindoles,Oxindole, Ajmalicine,Oxindole, Ajmalicine-Type,Oxindole, Macroline,Oxindole, Macroline-Type,Oxindoles, Ajmalicine,Oxindoles, Ajmalicine-Type,Oxindoles, Macroline,Oxindoles, Macroline-Type
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
May 1995, Arthritis and rheumatism,
H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
January 1983, Clinical therapeutics,
H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
November 1993, Arthritis and rheumatism,
H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
January 1983, Clinical therapeutics,
H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
June 1996, British journal of rheumatology,
H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
October 1995, Arthritis and rheumatism,
H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
June 2004, Annals of the rheumatic diseases,
H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
February 1988, Annals of the rheumatic diseases,
H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
November 2008, Arthritis and rheumatism,
H M Prupas, and L D Loose, and J S Spindler, and A J Dietz, and O B Gum, and M H Weisman, and G Gordon, and R E Wolf, and R A Turner, and R L Collins, and B F Germain, and P Katz, and S P Ballou, and F Wolfe, and J C Daniels, and P A April, and R F Willkens, and K Pariser, and B Hepburn, and T M Zizic, and N Ting, and M Mehrban
March 1985, Annals of the rheumatic diseases,
Copied contents to your clipboard!